GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Retained Earnings

BRAIN Biotech AG (XTER:BNN) Retained Earnings : €-98.72 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. BRAIN Biotech AG's retained earnings for the quarter that ended in Mar. 2024 was €-98.72 Mil.

BRAIN Biotech AG's quarterly retained earnings increased from Sep. 2023 (€-94.16 Mil) to Dec. 2023 (€0.00 Mil) but then declined from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€-98.72 Mil).

BRAIN Biotech AG's annual retained earnings declined from Sep. 2021 (€-79.51 Mil) to Sep. 2022 (€-85.20 Mil) and declined from Sep. 2022 (€-85.20 Mil) to Sep. 2023 (€-94.16 Mil).


BRAIN Biotech AG Retained Earnings Historical Data

The historical data trend for BRAIN Biotech AG's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Retained Earnings Chart

BRAIN Biotech AG Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only -67.92 -77.50 -79.51 -85.20 -94.16

BRAIN Biotech AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -89.99 - -94.16 - -98.72

BRAIN Biotech AG Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


BRAIN Biotech AG  (XTER:BNN) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


BRAIN Biotech AG (XTER:BNN) Business Description

Traded in Other Exchanges
Address
Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
Executives
Dr. Michael Majerus Supervisory Board
Dr. Georg Kellinghusen Supervisory Board
Michael Schneiders Board of Directors
Adriaan Moelker Board of Directors
Lukas Linnig Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines